Skip to main
GRAL

GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL Inc (GRAL) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 10%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

GRAIL is positioning itself as a leader in the multi-cancer early detection (MCED) space with their Galleri blood test, which has already shown promising results in clinical trials, including a 14% reduction in Stage IV cancer incidence and a 60% positive predictive value. The upcoming FDA approval for Galleri, as well as Medicare reimbursement, have the potential to unlock a substantial market opportunity for GRAIL. While there are concerns around adoption rates and cash burn, GRAIL's strong clinical performance and potential for international expansion make it a compelling investment opportunity.

Bears say

GRAIL is a healthcare company focused on developing technologies for early cancer detection. Despite its promising multi-cancer early detection blood test, the company faces several challenges that may hinder its growth potential. These include a slower-than-expected ramp-up in test volumes, potential structural constraints on the adoption curve, and potential cost headwinds from resumed royalty payments to Illumina. While GRAIL has a compelling clinical asset and upcoming FDA catalyst, its stock may be overvalued given these risks and the competitive landscape of the healthcare industry.

GRAIL Inc (GRAL) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 10% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRAIL Inc (GRAL) Forecast

Analysts have given GRAIL Inc (GRAL) a Buy based on their latest research and market trends.

According to 10 analysts, GRAIL Inc (GRAL) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRAIL Inc (GRAL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.